


Life Tech signs agreement with iPS Academia Japan

18 June 2012 | News | By BioSpectrum Bureau

Life Tech signs agreement with iPS Academia Japan



Singapore: Life Technologies has signed a non-exclusive agreement with iPS Academia Japan for its induced pluripotent stem (iPS) cell patent portfolio. The worldwide license will enable Life Technologies, a leading provider of innovative life science solutions, to expand its range of products and services for the iPS cell research community.

By leveraging its expertise in stem cell tool manufacturing and its global distribution network, Life Technologies is now positioned to develop and commercialize products designed to create iPS cells and differentiate them into any cell type for use in drug discovery and pre-clinical research. In addition to directly selling iPS cells, the license enables the company to provide iPS cell creation, differentiation and screening services for scientists around the world.

"iPS Academia Japan is pleased to grant a non-exclusive license and build a relationship with Life Technologies Corporation. Because iPS cells are gaining greater attention for uses in drug discovery and disease research as well as other areas of biotechnology, distribution of iPS cell products or provision of services is important for gaining momentum in iPS cell research," said Shosaku Murayama, president and Chief Executive Officer of AJ. "We believe that Life Technologies' business will contribute to boost research and development for practical application of iPS cell technology. We hope for further advancement of the iPS cell technology and its practical use in the coming years and we continue to support expanding the iPS cell technology by licensing our patent portfolio."

Scientists use iPS cell technology to create iPS cells from patient-derived adult cells. The iPS cells can then be differentiated into many primary cell types, such as neurons and hepatocytes, to be studied in the lab. The ability to develop cells from people with particular conditions of interest gives researchers the ability to study the genetics behind patient-specific diseases in an effort to test or develop new potential treatments.

"I am very pleased that Life Technologies, a worldwide biotechnology company, has signed an agreement for Kyoto University Patent," said Professor Shinya Yamanaka, who led the team that was first to generate iPS cells in 2006. "I hope it

will speed up the movement towards practical applications of iPS cell technology."

Mr Mark Stevenson, president and COO of Life Technologies, added: "Life Technologies has a heritage of providing the science community with the most innovative solutions designed to accelerate research. With this license now in place, we are furthering our commitment to the stem cell field and to developing a full breadth of products and services for our customers whether they are in basic research, drug discovery and development, or moving toward clinical applications."